Guerbet SA (FRA:4G8)

Market Cap	75.15M -59.9%
Revenue (ttm)	790.65M -3.7%
Net Income	-140.56M
EPS	-11.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21
Open	5.58
Previous Close	5.33
Day's Range	5.58 - 5.58
52-Week Range	5.33 - 18.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1901
• Employees: 2,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4G8

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error